EUCTR2005-003510-15-CZ进行中（未招募）不适用
A randomised, double-blind, double-dummy, parallel-group multicenter study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of 60 - 80 mg/day as oxycodone / naloxone prolonged release (OXN) compared to subjects taking oxycodone prolonged release tablets alone.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who are to be included in the study are those who meet all of the following screening criteria:
- •1. Male or female subjects at least 18 years or older.
- •2. Female subjects less than one year post-menopausal must have a negative serum pregnancy test recorded prior to the first dose of study medication, be non-lactating, and willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilization, implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasoectomised partner.
- •3. Moderate to severe chronic nonmalignant pain that requires around-the-clock opioid therapy (oxycodone equivalent of 60 - 80 mg/day).
- •4. Subjects who require continuation of daily opioid treatment and are likely to benefit from WHO step III opioid therapy for the duration of the study.
- •5. Subjects must be willing to discontinue their current opioid analgesic routine.
- •6. Subjects must report constipation caused or aggravated by opioids.
- •7. Subjects must be willing to discontinue their current laxative regimen.
- •8. Subjects must comply with the use of oral bisacodyl as laxative rescue medication. Rescue will be permitted no sooner than 72 hours after the subject’s most recent bowel movement (BM).
- •9. Subjects taking daily fiber supplementation or bulking agents are eligible if they can be maintained on a stable dose and regimen throughout the study, and in the investigator’s opinion are willing and able to maintain adequate hydration.
- •10. Subjects willing and able to participate in all aspects of the core study, including use of oral medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, and compliance with protocol requirements as evidenced by providing written, informed consent.
- •11. Subjects with pre-study, non-opioid analgesics, and all other concomitant medications, including those medications for the treatment of depression, that are thought to be stable, are considered necessary for the subject’s welfare, are anticipated to remain stable throughout the Double-blind Period of the study, and are to be continued under the supervision of the investigator, are eligible.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who are to be excluded from the study are those who meet any of the following screening criteria:
- •1. Females who are pregnant (positive ß-hCG test) or lactating.
- •2. Any history of hypersensitivity to oxycodone, naloxone, related products, and
- •other ingredients.
- •3. Any contraindication to bisacodyl and other ingredients
- •4. Subjects with evidence of significant structural abnormalities of the gastrointestinal (GI) tract (e.g., bowel obstruction, strictures) or any diseases/conditions that affect bowel transit (e.g., ileus, hypothyroidism).
- •5. Subjects with cancer associated pain.
- •6. Active alcohol or drug abuse and/or history of opioid abuse.
- •6a. Subjects with a positive urine drug test at screening visit 1, which
- •indicates unreported illicit drug use or unreported use of a concomitant
- •medication not required to treat the subjects medical condition(s).
- •7. Subjects with Rheumatoid Arthritis (RA).
- •8. Subjects with evidence of clinically unstable disease, as determined by medical history, clinical laboratory tests, ECG results, and physical examination that, in the investigator’s opinion, preclude entry into the study.
- •9. Subjects with evidence of impaired liver/kidney function upon entry into the study defined as aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels >3 times the upper limit of normal; gamma glutamyl transpeptidase (GGT or GGTP) =5 times the upper limit of normal; total bilirubin level outside of the reference range; and/or creatinine level outside of the reference range or > 2 mg/dl, or in the investigator’s opinion, liver and/or kidney impairment to the extent that the subject should not participate in this study.
- •10. Subjects who have required treatment for the diagnosis of irritable bowel syndrome (IBS).
- •11. Subjects receiving hypnotics or other central nervous system (CNS) depressants that, in the investigator’s opinion, may pose a risk of additional CNS depression with opioids study medication.
- •12. Subjects receiving opioid substitution therapy for opioid addiction (e.g., methadone or buprenorphine).
- •13. Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days of study entry (defined as the start of the Screening Period).
- •14. Subjects presently taking, or who have taken naloxone or naltrexone within 30 days of study entry (defined as the start of the Screening Period).
- •15. Surgery within 2 months prior to the start of the Screening Period, or planned surgery during the12-week Double-blind Phase that may affect GI motility or pain.
- •16. Subjects with any situation in which opioids are contraindicated, severe
- •respiratory depression with hypoxia and/or hypercapnia, severe chronic
- •obstructive lung disease, cor pulmonale, severe bronchial asthma, paralytic
- •17. Subjects with myxoedema, hypothyroidism, Addison`s disease, increase of
- •intracranial pressure and/or epilepsy
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, double-dummy, parallel-group multicenter study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of 60 - 80 mg/day as oxycodone / naloxone prolonged release (OXN) compared to subjects taking oxycodone prolonged release tablets alone.Moderate to severe chronic non-malignant pain that requires around-the-clock opioid therapy and also constipation secondary to opioid treatment.MedDRA version: 7.1Level: ptClassification code 10003988EUCTR2005-003510-15-HUMundipharma Research GmbH & Co. KG480
进行中（未招募）
不适用
A randomised, double-blind, double-dummy, parallel-group multicentre study to demonstrate non-inferiority in pain and locomotor function and improvement in symptoms of constipation in subjects with moderate to severe pain due to osteoarthritis (OA) of the knee and/or hip taking oxycodone equivalent of 20 - 80 mg/day as oxycodone/naloxone prolonged release (OXN PR) compared to subjects taking oxycodone prolonged release tablets (OxyPR) alone.Pain, locomotor function and improvement in constipation in osteoarthritis patients taking opioidsMedDRA version: 9.1Level: LLTClassification code 10031161Term: OsteoarthritisMedDRA version: 9.1Level: LLTClassification code 10021175Term: Iatrogenic constipationEUCTR2008-002670-36-CZMundipharma Research GmbH & Co. KG260
进行中（未招募）
不适用
A randomised, double-blind, double-dummy, parallel-group multicenter study to demonstrate improvement in symptoms of constipation and non-inferiority in analgesic efficacy in subjects with non-malignant or malignant pain that requires around-the-clock opioid therapy taking 50/25-80/40 mg twice daily as oxycodone/naloxone prolonged release (OXN PR) tablets compared to subjects taking 50-80 mg twice daily oxycodone prolonged release (OxyPR) tablets alone. - TEMPiTThe intended indication is:Severe pain, which can be adequately managed only with opioid analgesics. The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.MedDRA version: 17.0Level: PTClassification code 10058019Term: Cancer painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2010-021995-27-CZMundipharma Research GmbH & Co. KG270
进行中（未招募）
不适用
A randomised, double-blind, double-dummy, parallel-group multicentre study to demonstrate non-inferiority in pain and locomotor function and improvement in symptoms of constipation in subjects with moderate to severe pain due to osteoarthritis (OA) of the knee and/or hip taking oxycodone equivalent of 20 - 80 mg/day as oxycodone/naloxone prolonged release (OXN PR) compared to subjects taking oxycodone prolonged release tablets (OxyPR) alone.Pain, locomotor function and improvement in constipation in osteoarthritis patients taking opioidsMedDRA version: 9.1Level: LLTClassification code 10031161Term: OsteoarthritisMedDRA version: 9.1Level: LLTClassification code 10021175Term: Iatrogenic constipationEUCTR2008-002670-36-FIMundipharma Research GmbH & Co. KG200
进行中（未招募）
1 期
A study to demonstrate improvement in symptoms of constipation and non-inferiority in analgesic efficacy in subjects with non-malignant or malignant pain that requires around-the-clock opioid therapy taking oxycodone/naloxone prolonged release (OXN PR) tablets compared to subjects taking oxycodone prolonged release (OxyPR) tablets alone.EUCTR2010-021995-27-ROMundipharma Research GmbH & Co. KG243